The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis†
Open accessAbstract
For more than a century and a half, the description of a liver as "cirrhotic" was sufficient to connote both a pathological and clinical status, and to assign the prognosis of a patient with liver disease. However, as our interventions to treat advanced liver disease have progressed (e.g., antiviral therapies), the inadequacy of a simple one-stage description for advanced fibrotic liver disease has become increasingly evident. Until recently, refining the diagnosis of cirrhosis into more than one stage hardly seemed necessary when there were no interventions available to arrest its progression. Now, however, understanding the range of potential outcomes based on the severity of cirrhosis is essential in order to predict outcomes and individualize therapy. This position paper, rather than providing clinical guidelines, attempts to catalyze a reformulation of the concept of cirrhosis from a static to a dynamic one, creating a template for further refinement of this concept in the future. We already make the clinical distinction between compensated and decompensated cirrhosis, and are incrementally linking these clinical entities to quantitative variables such as portal pressure measurements and emerging noninvasive diagnostics. Moreover, mounting evidence suggests that cirrhosis encompasses a pathological spectrum which is neither static nor relentlessly progressive, but rather dynamic and bidirectional, at least in some patients. Thus, there is a pressing need to redefine cirrhosis in a manner that better recognizes its underlying relationship to portal hypertension and related circulatory changes, and more faithfully reflects its progression, reversibility and prognosis, ultimately linking these parameters to clinically relevant outcomes and therapeutic strategies. The Child-Pugh and Model for End-Stage Liver Disease (MELD) scores are currently deployed to define prognosis by modeling hepatic dysfunction, but do not provide direct evidence of the stage or dynamic state of cirrhosis. The need for more refined cirrhosis staging is especially germane given the increasing use of effective antiviral treatments in patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) cirrhosis and the emergence of effective antifibrotic agents, wherein we must define favorable or unfavorable endpoints that correlate with a discrete clinical outcome in patients with cirrhosis. The normal liver has only a small amount of fibrous tissue in relation to its size. As a result of continued liver injury, however, there is progressive accumulation of extracellular matrix, or scar. Although different chronic liver diseases are characterized by distinct patterns of fibrosis deposition,1 the development of cirrhosis represents a common outcome leading to similar clinical consequences that impose an increasing burden in clinical practice. Cirrhosis is defined histologically as a diffuse process in which the normal anatomical lobules are replaced by architecturally abnormal nodules separated by fibrous tissue.2 Progressive histological stages have been defined in the process leading to the development of cirrhosis. Among the more common staging systems, the METAVIR scale is distinguished by four stages, with stage F0 representing lack of fibrosis; stage F1, portal fibrosis; stage F2, periportal fibrosis; stage F3, bridging fibrosis; and, finally, stage F4 representing cirrhosis.3 Similarly, the Ishak4 and Scheuer scoring systems5, 6 attempt to semiquantitatively define progressive fibrosis based on the pattern and relative amounts of scar within a liver biopsy specimen. In this context, once fibrosis reaches the final stages, the diagnosis of cirrhosis is established and the process is considered "end-stage" from a pathological perspective. HVPG, hepatic venous pressure gradient; LSM, liver stiffness measurement. Cirrhosis has also been increasingly defined by clinical outcomes. In this context, cirrhosis is distinguished between compensated and decompensated stages, with different features, prognoses and predictors of death.7 Within the compensated stage, two subpopulations have been identified based on the absence or presence of varices, each of which confers a distinct prognosis. Decompensated cirrhosis is defined by the development of clinically evident complications of portal hypertension (ascites, variceal hemorrhage, hepatic encephalopathy) or liver insufficiency (jaundice). The decompensated stage can be subclassified further into a more severe stage defined by the development of recurrent variceal hemorrhage, refractory ascites, hyponatremia and/or hepatorenal syndrome. Portal hypertension is the earliest and most important consequence of cirrhosis and underlies most of the clinical complications of the disease. Portal hypertension results from an increased intrahepatic resistance combined with increased portal (and hepatic arterial) blood flow. The increased intrahepatic resistance is the result of architectural distortio
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histological grading and staging of chronic hepatitis
Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., Denk, H., Desmet, V., Korb, G., MacSween, R. N. M., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,029
Knodell, R. G., Ishak, K. G., Black, W. C., Chen, T. S., Craig, R., Kaplowitz, N., Kiernan, T. W., & Wollman, J. (1981) · Hepatology · doi:10.1002/hep.1840010511 · Cited by 3,522
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
D'Amico, G., Garcia-Tsao, G., & Pagliaro, L. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.013 · Cited by 2,687
Self-citationMechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Self-citationSampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
Regev, A., Berho, M. E., Jeffers, L. J., Milikowski, C., Molina, E. G., Pyrsopoulos, N., Feng, Z.-Z., Reddy, K. R., & Schiff, E. R. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04396-4 · Cited by 2,093
Ripoll, C., Groszmann, R., Garcia–Tsao, G., Grace, N., Burroughs, A., Planas, R., Escorsell, A., Garcia–Pagan, J. C., Makuch, R., Patch, D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.024 · Cited by 1,183
Self-citationAn Update on Terminology and Reporting
Batts, K. P., & Ludwig, J. (1995) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199512000-00007 · Cited by 1,080
Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis
Groszmann, R. J., Garcia-Tsao, G., Bosch, J., Grace, N. D., Burroughs, A. K., Planas, R., Escorsell, A., Garcia-Pagan, J. C., Patch, D., Matloff, D. S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044456 · Cited by 1,005
Self-citationVizzutti, F., Arena, U., Romanelli, R. G., Rega, L., Foschi, M., Colagrande, S., Petrarca, A., Moscarella, S., Belli, G., Zignego, A. L., et al. (2007) · Hepatology · doi:10.1002/hep.21665 · Cited by 714
Self-citation
Cited by
BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319
Garcia‐Tsao, G., Abraldes, J. G., Berzigotti, A., & Bosch, J. (2017) · Hepatology · doi:10.1002/hep.28906 · Cited by 2,154
Self-citationBerzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
Tsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60121-5 · Cited by 1,740
Arvaniti, V., D'Amico, G., Fede, G., Manousou, P., Tsochatzis, E., Pleguezuelo, M., & Burroughs, A. K. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.019 · Cited by 1,167
Pathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894
Self-citationBarr, R. G., Ferraioli, G., Palmeri, M. L., Goodman, Z. D., Garcia-Tsao, G., Rubin, J., Garra, B., Myers, R. P., Wilson, S. R., Rubens, D., et al. (2015) · Radiology · doi:10.1148/radiol.2015150619 · Cited by 632
Self-citationCarrat, F., Fontaine, H., Dorival, C., Simony, M., Diallo, A., Hezode, C., De Ledinghen, V., Larrey, D., Haour, G., Bronowicki, J.-P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32111-1 · Cited by 628
Noninvasive Methods to Assess Liver Disease in Patients With Hepatitis B or C
Castera, L. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.017 · Cited by 605
Evolving challenges in hepatic fibrosis
Friedman, S. L. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.97 · Cited by 581
Self-citationCompeting risks and prognostic stages of cirrhosis: a 25‐year inception cohort study of 494 patients
D'Amico, G., Pasta, L., Morabito, A., D'Amico, M., Caltagirone, M., Malizia, G., Tinè, F., Giannuoli, G., Traina, M., Vizzini, G., et al. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12721 · Cited by 547
Clinical states of cirrhosis and competing risks
D'Amico, G., Morabito, A., D'Amico, M., Pasta, L., Malizia, G., Rebora, P., & Valsecchi, M. G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.020 · Cited by 536
Colecchia, A., Montrone, L., Scaioli, E., Bacchi–Reggiani, M. L., Colli, A., Casazza, G., Schiumerini, R., Turco, L., Di Biase, A. R., Mazzella, G., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.035 · Cited by 529
Self-citationHepatic fibrosis 2022: Unmet needs and a blueprint for the future
Friedman, S. L., & Pinzani, M. (2022) · Hepatology · doi:10.1002/hep.32285 · Cited by 430
Self-citationClinical evidence for the regression of liver fibrosis
Ellis, E. L., & Mann, D. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.09.024 · Cited by 411
Corpechot, C., Carrat, F., Poujol-Robert, A., Gaouar, F., Wendum, D., Chazouillères, O., & Poupon, R. (2012) · Hepatology · doi:10.1002/hep.25599 · Cited by 351
Singh, S., Fujii, L. L., Murad, M. H., Wang, Z., Asrani, S. K., Ehman, R. L., Kamath, P. S., & Talwalkar, J. A. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.07.034 · Cited by 352
Non invasive evaluation of portal hypertension using transient elastography
Castera, L., Pinzani, M., & Bosch, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.005 · Cited by 326
Self-citationFibrosis and alcohol-related liver disease
Lackner, C., & Tiniakos, D. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.003 · Cited by 322
Villa, E., Bianchini, M., Blasi, A., Denys, A., Giannini, E. G., de Gottardi, A., Lisman, T., de Raucourt, E., Ripoll, C., & Rautou, P.-E. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.003 · Cited by 318
Cancer and liver cirrhosis: implications on prognosis and management
Pinter, M., Trauner, M., Peck-Radosavljevic, M., & Sieghart, W. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000042 · Cited by 295
Prognostic indicators of survival in patients with compensated and decompensated cirrhosis
Zipprich, A., Garcia‐Tsao, G., Rogowski, S., Fleig, W. E., Seufferlein, T., & Dollinger, M. M. (2012) · Liver International · doi:10.1111/j.1478-3231.2012.02830.x · Cited by 280
Self-citationBosch, J., Groszmann, R. J., & Shah, V. H. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.003 · Cited by 252
Liu, L., You, Z., Yu, H., Zhou, L., Zhao, H., Yan, X., Li, D., Wang, B., Zhu, L., Xu, Y., et al. (2017) · Nature Materials · doi:10.1038/nmat5024 · Cited by 163
Beyond scoring: a modern interpretation of disease progression in chronic liver disease
Rosselli, M., MacNaughtan, J., Jalan, R., & Pinzani, M. (2013) · Gut · doi:10.1136/gutjnl-2012-302826 · Cited by 96
Self-citationWhy Do So Many Nonalcoholic Steatohepatitis Trials Fail?
Ratziu, V., & Friedman, S. L. (2023) · Gastroenterology · doi:10.1053/j.gastro.2020.05.046 · Cited by 88
Self-citationNascimbeni, F., Lebray, P., Fedchuk, L., Oliveira, C. P., Alvares-da-Silva, M. R., Varault, A., Ingiliz, P., Ngo, Y., de Torres, M., Munteanu, M., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.037 · Cited by 82
Review article: the reversibility of cirrhosis
Sohrabpour, A. A., Mohamadnejad, M., & Malekzadeh, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12044 · Cited by 80
Lyu, C., Kong, W., Liu, Z., Wang, S., Zhao, P., Liang, K., Niu, Y., Yang, W., Xiang, C., Hu, X., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01019-z · Cited by 67
Simon, T. G., Kim, M. N., Luo, X., Yang, W., Ma, Y., Chong, D. Q., Fuchs, C. S., Meyerhardt, J. A., Corey, K. E., Chung, R. T., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.12.022 · Cited by 57
Insulin-Like Growth Factor-1 Deficiency and Cirrhosis Establishment
de la Garza, R. G., Morales-Garza, L. A., Martin-Estal, I., & Castilla-Cortazar, I. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2761w · Cited by 55
Targeting the Gut–Liver Axis in Cirrhosis: Antibiotics and Non-Selective β-Blockers
Madsen, B. S., Havelund, T., & Krag, A. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0044-1 · Cited by 38
The Human Gut Microbiome in Liver Diseases
Davis, B., & Bajaj, J. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1602763 · Cited by 34
Shao, M., Zhang, X., Sun, J., Dong, H., Han, X., Yang, Q., Chen, R., Shen, L., Xu, L., Wang, L., et al. (2025) · Exploration · doi:10.1002/exp.70000 · Cited by 26
“Pericarcinomatous tissue of patients with liver cancer was collected as fibrosis replacements to identify the pathological STAT3 activation at different stages of liver fibrosis [27].”
Regression of HCV cirrhosis: Time will tell
Garcia‐Tsao, G. (2018) · Hepatology · doi:10.1002/hep.29720 · Cited by 15
Precise cell therapy for liver fibrosis: Endothelial cell and macrophage therapy
Deng, L., Wu, B., Liang, K., Liao, H., & Du, Y. (2022) · iLIVER · doi:10.1016/j.iliver.2022.11.002 · Cited by 4
Metadata
- Authors
- Garcia‐Tsao, G., Friedman, S., Iredale, J., & Pinzani, M.
- Venue
- Hepatology
- Published
- 2010-04
- Volume
- 51
- Issue
- 4
- Pages
- 1445-1449
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2037788436
- Cited by
- 538
- References
- 28
- FWCI
- 11.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.